NIH awards seven new vaccine adjuvant discovery contracts

June 29, 2015 12:51 pm

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.

“The goal of this research is to identify novel adjuvant candidates that safely and selectively boost vaccine-induced immune responses,” said NIAID Director Anthony S. Fauci, M.D. “Such adjuvants could be used to improve current vaccines, extend the vaccine supply or enhance vaccine efficacy in people with immature or weakened immune systems, such as infants and the elderly.”

Only three adjuvants — alum, AS04 and AS03 — are components of vaccines approved by the U.S. Food and Drug Administration for human use. Alum, which is composed of aluminum salts, is included in many U.S.-licensed vaccines, including those that protect against hepatitis B and pneumococcal infections. AS04, a combination of alum and an immune-stimulating lipid (fat), is included in the vaccine Cervarix, which prevents infection with the two human papillomavirus types that cause most cervical cancers.  The oil-in-water adjuvant AS03 is included in a vaccine for use in the event of an H5N1 bird flu epidemic.

NIAID adjuvant discovery contracts awarded in 2003 and 2009 identified adjuvants that trigger a small set of receptors of the innate, or inborn, immune system. The innate immune response helps shape adaptive, or acquired, immunity, which confers long-term protection from infection by specific pathogens. The new NIAID awards aim to expand the scope of adjuvant research by searching for any compound involved in the activation of the adaptive immune system.